^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Regimen:TC (cyclophosphamide + docetaxel)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer: Invasive Breast Cancer…PREOPERATIVE/ADJUVANT THERAPY REGIMENS…HER2-Negative Preferred Regimens…TC2…Docetaxel 75mg/m2IV day 1…Cyclophosphamide 600mg/m2 IV day 1…
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Breast
    Title:

    Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study

    Published date:
    08/27/2020
    Excerpt:
    Patients with node negative and HER2-negative breast cancer treated with...docetaxel and cyclophosphamide (DC)...Adjuvant chemotherapy with four cycles of DC in a select population of node negative breast cancer was associated with encouraging long-term survival.
    DOI:
    10.1016/j.breast.2020.08.002